Holds one active US DMF for carfilzomib, filing since 2015. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 7 markets.
Holds one active US DMF for carfilzomib, filing since 2023. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 6 markets.
Holds one active US DMF for carfilzomib, filing since 2023. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 1 market.
Holds one active US DMF for carfilzomib, filing since 2025. Its 2024 FDA inspection closed as NAI.
Holds one active US DMF for carfilzomib, filing since 2024. Its GMP is recognised in 5 markets.
Holds one active US DMF for carfilzomib, filing since 2025. Its 2024 FDA inspection closed as NAI.
Holds one active US DMF for carfilzomib, filing since 2025. Its GMP is recognised in 4 markets.
Holds one active US DMF for carfilzomib, filing since 2025. Its 2025 FDA inspection closed as VAI.
Holds one active US DMF for carfilzomib, filing since 2023. Its GMP is recognised in 1 market.
Holds one active US DMF for carfilzomib, filing since 2025.
Holds 2 active US DMFs for carfilzomib, filing since 2025.
The names are listed below. The filings, inspection history and GMP certificates behind each one are available with a free account.
This page filters the worldwide Carfilzomib manufacturer list to companies based in China. The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Read the full method.
Tell us which markets you need to file in. These suppliers come back tiered for those markets, with the price corridor and an RFI sheet.
Start for free